|
Jul 29
|
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
|
|
Jul 22
|
Top Midday Decliners
|
|
Jul 22
|
ProMIS Neurosciences Announces Private Placement Financing
|
|
Jul 22
|
ProMIS Neurosciences Announces $0.8 Million Registered Direct Offering, Priced At-the-Market Under Nasdaq Rules
|
|
Jul 21
|
BC-Most Active Stocks
|
|
Jul 21
|
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
|
|
Mar 13
|
ProMIS Neurosciences Showcases Preclinical Data on Platform Derived Vaccines for Neurodegenerative Diseases at the American Academy of Neurology 2025 Annual Meeting
|
|
Mar 11
|
ProMIS Neurosciences to Participate in the 37th Annual Roth Conference
|
|
Feb 25
|
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease
|
|
Jul 30
|
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
|
|
Jul 26
|
ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial
|
|
Jul 26
|
ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing
|
|
Jan 22
|
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
|
|
Dec 20
|
ProMIS Neurosciences Announces Publication on Novel Target for ALS
|
|
Nov 14
|
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights
|
|
Aug 21
|
ProMIS Neurosciences Announces $20.4 Million Private Placement Financing
|
|
Jun 29
|
CORRECTION: Updated URL to Access ProMIS Annual Meeting of Shareholders on June 29, 2023 at 9:30am Eastern Time
|